Global Pharmatech Receives Two New Drug Approvals for the Singapore Market JILIN, China, June 17 /Xinhua-PRNewswire/ -- Global Pharmatech, Inc. (OTC PK: GBLP), a company which combines R&D of botanical drug products, manufacturing, and sales and marketing for the Over-the-Counter (OTC) and prescription drug markets, announced that it's wholly owned subsidiary, Jilin Natural Pharmatech, has received approval from the Center for Drug Administration, Singapore Health Sciences Authority, for two new herbal drug products, Qing-Chang-Pai-Du and Qing-Xue capsules. Dr. Sun Xiaobo, President and CEO of Global Pharmatech, stated, 'We are pleased with our ability to continue to execute on our growth strategy and expand our sales and marketing reach outside of China and into other Asian markets such as Singapore. The approval by the Singapore Health Sciences Authority for our two newly developed herbal products is a testament to our own experienced R&D team and also to the potential of the herbal drug market outside of China. We hope to continue this expansion trend into other Asian countries in the near future and further demonstrate the broad reach and demand for our products.' The patents of these two drugs are owned by Jilin Natural Pharmatech with the raw materials being supplied by Jilin BCT Pharmacy, another subsidiary of Global Pharmatech. The products will be manufactured in Singapore by Kim Sin Medication Supply and distributed by Singapore Huay Feng Hang PTE, Ltd. Going forward, Global Pharmatech products for the Singapore market will be branded with the approved BCT trademark. Qing-Chang-Pai-Du capsule is mainly used for regulating gastrointestinal functions. Qing-Xue capsule is used to lower blood cholesterol levels. Combined with the two other previously approved herbal drug products, Yue-Zhi and Lu-Rong-Jian-Tian capsules, Global Pharmatech now has a total of four drugs for the Singapore market. About Global Pharmatech Global Pharmatech, through its subsidiaries, develops, manufactures and markets proprietary drugs that are based on Traditional Chinese Medicine while utilizing modern facilities and advanced R&D technologies. Global Pharmatech offers a full range of 'start to finish' biotech services, from R&D and testing, to manufacturing drugs in liquid and solid dose forms, to sales and marketing. Global Pharmatech utilizes unique extraction methods and innovative techniques that have been developed by its R&D team. Global Pharmatech's core business to date has been licensing its R&D patents and technologies for botanical/biological drug products. Global Pharmatech's operations are currently based in the People's Republic of China with sales distribution in China, Malaysia, Singapore and Indonesia. Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 This news release contains forward-looking statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason. For more information, please contact: Brandi Piacente, Investor Relations, The Anne McBride Co. Tel: +1-212-983-1702 x208 Email: DATASOURCE: Global Pharmatech, Inc. CONTACT: Brandi Piacente of The Anne McBride Co., +1-212-983-1702 x208, or , for Global Pharmatech, Inc.

Copyright